Inovio Pharmaceuticals Inc INO

NAS: INO | ISIN: US45773H2013   10/05/2024
10,65 USD (-4,74%)
(-4,74%)   10/05/2024

1 mei 2024 · INOVIO Reports Inducement Grants Under Inducement Plan · Persbericht

29 april 2024 · INOVIO to Participate in Upcoming Investor Conferences in May · Persbericht

29 april 2024 · INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 · Persbericht

16 april 2024 · INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants · Persbericht

26 maart 2024 · INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine · Persbericht

6 maart 2024 · INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights · Persbericht

6 maart 2024 · Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting · Persbericht

21 februari 2024 · INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 · Persbericht

7 februari 2024 · INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

2 februari 2024 · INOVIO Reports Inducement Grant Under Inducement Plan · Persbericht

23 januari 2024 · INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split · Persbericht

22 januari 2024 · INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader · Persbericht

4 januari 2024 · INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) · Persbericht

3 januari 2024 · INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program · Persbericht

9 november 2023 · INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights · Persbericht

1 november 2023 · INOVIO Reports Inducement Grants Under Inducement Plan · Persbericht

26 oktober 2023 · INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 · Persbericht

10 oktober 2023 · INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program · Persbericht

28 september 2023 · Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million · Persbericht

7 september 2023 · INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis · Persbericht

Mijn selecties